Skip to main content
main-content
Top

The CREDENCE trial

The CREDENCE trial was the first to directly test the cardiovascular and renal benefits of a SGLT2 inhibitor (canagliflozin) in people with type 2 diabetes and albuminuric chronic kidney disease.

In the primary analysis, canagliflozin significantly reduced the risk for renal progression and death from renal or cardiovascular causes, and a more recent analysis showed this applied regardless of whether patients had pre-existing cardiovascular disease.

Receive the latest EASD 2019 coverage direct to your inbox


The CREDENCE investigators do not anticipate having new data ready in time for the 55th EASD Annual Meeting (EASD 2019), but will provide an overview of the findings to date:

CREDENCE 
Tuesday, September 17, 12:00–13:00, Joslin Hall, Fira Barcelona Gran Via, Spain 
Session Chair: V. Perkovic, Australia

  1. Introduction and design. C. Pollock, Australia
  2. Renal outcomes. H. J. Lambers Heerspink, Netherlands
  3. Cardiovascular and safety outcomes. K. W. Mahaffey, USA
  4. Commentary. M. A. Nauck, Germany


What our Editorial Board said:

John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

Back to the EASD 2019 conference hub